Bartek Dabek

MD, Precision Oncology, Big Data but the opposite. For me the action is the juice.

[Bartek Dabek @outliersbio]

@dr_yakupergun @oncologician @BalazsHalmosMD @EGFRResisters @RManochakian @VivekSubbiah @Larvol 2

[Bartek Dabek @outliersbio]

@pashtoonkasi @CCR_AACR @AACR @OncoAlert Never understood why this is not a big deal and why this drug is not developed more quickly and aggressively. Just few trials in US

[Bartek Dabek @outliersbio]

@Cancer_Cell So after all these years we are still analyzing in silico data with different prediction tools instead wet lab validation?

[Bartek Dabek @outliersbio]

@OncoAdvLukas @pashtoonkasi @OncoAlert Most of my patients prefer iv over sc

[Bartek Dabek @outliersbio]

@jsoriamd @oncologician I have skim read it…is this paper changing anything…any new biomarker ? New treatment effectiveness measure ? No delineation between Pole, MSI-H , high PDL1 cancers !

[Bartek Dabek @outliersbio]

@KentsisResearch @YKazansky At first I was treating with Nivolumab , then Nivolumab Lenvatinib with no effect and then I added EZHi instead of Lenvatinib. From what I see Nivolumab is not the way but there are no AEs and combo is ongoing

[Bartek Dabek @outliersbio]

@KentsisResearch @YKazansky I treat 2 ( one with MYCN amplification ) sarcoma patients with EZH inhibitor and both responded similarly to cell lines that you presented, feeling better and little tumor regression but it seems that something is missing and they need another drug…if only I could get ATR inh

[Bartek Dabek @outliersbio]

@adbeggs @nanopore Very fast and somewhat funny that you wait 7-21 days for pathology report, same for CT scan same for surgery and 24 hours for whole genome and then you have 28 days for screening and randomization

[Bartek Dabek @outliersbio]

@Eddie_Cliff @NicoGagelmann @nihardesai7 @VincentRK @DianaNrco @DrJFriedberg @VivekSubbiah @doctorpemm How come Annals are higher than JCO ?

[Bartek Dabek @outliersbio]

@KenOliveLab @UmutDisel @CD_AACR Can we get that in Europe?

[Bartek Dabek @outliersbio]

@InnovOncology @CD_AACR @OncBrothers @OncoAlert @oncodaily @TaliLev123 @ElizSMcKenna Why are they not listing lof and gof mutations ?

[Bartek Dabek @outliersbio]

@artofarchitect What are these lamps ?

[Bartek Dabek @outliersbio]

@jacobadashek @UmutDisel @Dr_R_Kurzrock @VivekSubbiah @PavlosMsaouel @NicoleKuderer @HemOncFellows @APConley77 @realbowtiedoc @BenWestphalen @montypal @neerajaiims @PGrivasMDPhD @DrBonillaOnc I have similar case with 12 months ongoing response

[Bartek Dabek @outliersbio]

@tangming2005 I’m yet to read a case report where any of these programs helped any patient. This field is old enough that pembrolizumab is losing its patent and besides MSI-H that you can do with simple IHC no other biomarker is there.

[Bartek Dabek @outliersbio]

@mcten We call him Jeff Green 2.0

[Bartek Dabek @outliersbio]

@NatureRevCancer Is there anything in this article I can directly translate to clinics. Any piece of information ?

[Bartek Dabek @outliersbio]

@VivekSubbiah @D_B_McConnell When can we expect a ph1 ?

[Bartek Dabek @outliersbio]

@Dr_ImmunoMan_D Was there a study that investigated a patient with multiple lesions - all responding to ICI and then after weeks/months of treatment there is resistance and reccurent growth in one of lesions. I have a lot of this kind of patients

[Bartek Dabek @outliersbio]

@VPrasadMDMPH Belzutifan is out of stock and is in many trials that were put on hold, same was with BCG that was in many trials. It is some conspiracy but Cisplatin FU or LV hold many trials and generate lots of losses for same pharma